Furmonertinib trials for Non-Small-Cell Lung Cancer
All Furmonertinib trials · All Non-Small-Cell Lung Cancer trials
7
Recruiting trials
Phase breakdown
Phase 2 6Not applicable 1
Recruiting trials studying Furmonertinib for Non-Small-Cell Lung Cancer
- A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
- Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
- Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
- High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
- High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
- To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Common questions
How many trials study Furmonertinib for Non-Small-Cell Lung Cancer?
7 recruiting trials.
Is this list complete?
No. For the full record, search ClinicalTrials.gov.